NAD+ IV Therapy: What It Costs, What It Does, and What the Trials Show

NAD+ IV therapy rests on a premise that is genuinely true and a conclusion that does not follow from it. Nicotinamide adenine dinucleotide is a coenzyme central to cellular energy metabolism, and its levels decline with age. That much is well established.

Whether infusing it intravenously restores anything measurable is a different question, and it is the one the clinics rarely address.

What the human trials actually studied

Almost all of the human evidence is on oral precursors, not on IV NAD+ itself. This is the single most important thing to understand about the category — the trials people cite and the product people buy are not the same intervention.

A 2026 Nature Metabolism study compared three different NAD+ boosters on circulatory NAD and microbial metabolism in humans, finding that they do not behave equivalently. A 2026 Lancet Neurology trial tested NAD+ precursor supplementation alongside individualised exercise in Friedreich ataxia — a real randomised design in a defined patient population.

Why IV is proposed

The argument is bioavailability. NAD+ is a large, charged molecule, and the case for infusion is that oral NAD+ is broken down in the gut into precursors before absorption — so intravenous delivery bypasses that.

The counter-argument is that cells may not take up intact NAD+ efficiently either. Circulating NAD+ still has to cross cell membranes to matter, and much of the proposed mechanism for oral precursors is precisely that cells prefer to build NAD+ from smaller components. If that is true, infusing the finished molecule is not obviously the superior route.

Cost

The cost gradient runs opposite to the evidence gradient. The most expensive option has the least human trial data behind it; the cheapest has the longest history. That is worth sitting with before booking a course.

The infusion experience

NAD+ infusions are characteristically uncomfortable, and this is consistently reported rather than rare. Chest tightness, nausea, flushing, abdominal cramping and a general sense of pressure are common, and clinics manage them by slowing the drip — which is why sessions run to hours rather than minutes.

Where an IV genuinely makes sense

Intravenous administration is the right route when a compound has poor oral bioavailability, a narrow therapeutic window requiring precise control, or an urgent clinical indication. For a wellness intervention in a healthy person with no measured deficiency, none of those apply.

• There is no established NAD+ deficiency state that is routinely diagnosed and treated.

• There is no standard assay in general clinical use for tissue NAD+ status.

• There is no target level to infuse towards.

• So there is no measurement establishing a starting point, an endpoint, or whether anything changed.

If the goal is fatigue

Fatigue is the reason most people book these. It has common, testable, treatable causes that are worth excluding first — iron deficiency, thyroid dysfunction, sleep apnoea, vitamin D and B12 status, depression and medication effects. Each has a test and a treatment; NAD+ IV has neither.

The peptides for energy guide covers the same reasoning across the wider category, and the NAD+ injection guide covers the subcutaneous route specifically.